Analyst Ratings For Bausch Health Companies Inc (NYSE:BHC)
Today, Morgan Stanley set its price target on Bausch Health Companies Inc (NYSE:BHC) to $32.00 per share.
There are 7 Buy Ratings, 6 Hold Ratings, 3 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Bausch Health Companies Inc (NYSE:BHC) is Hold with a consensus target price of $25.7857 per share, a potential 14.86% upside.
Some recent analyst ratings include
- 12/14/2018-Bausch Health Companies Inc (NYSE:BHC) gets upgraded to Buy by HC Wainwright
- 11/13/2018-Bausch Health Companies Inc (NYSE:BHC) had its Hold rating reiterated by BMO Capital Markets with a $26.00 price target
- On 10/16/2018 Christina Ackermann, EVP, sold 19,946 with an average share price of $24.98 per share and the total transaction amounting to $498,251.08.
- On 9/14/2018 Joseph C Papa, CEO, bought 30,000 with an average share price of $22.32 per share and the total transaction amounting to $669,600.00.
- On 9/14/2018 Paul Herendeen, CFO, bought 10,000 with an average share price of $22.61 per share and the total transaction amounting to $226,100.00.
- On 9/13/2018 Schutter Richard U De, Director, bought 125,000 with an average share price of $23.96 per share and the total transaction amounting to $2,995,000.00.
- On 5/15/2018 Schutter Richard U De, Director, bought 15,000 with an average share price of $21.83 per share and the total transaction amounting to $327,450.00.
- On 5/15/2018 Schutter Richard U De, Director, bought 10,000 with an average share price of $21.80 per share and the total transaction amounting to $218,000.00.
- On 3/13/2018 Joseph C Papa, CEO, bought 30,000 with an average share price of $16.05 per share and the total transaction amounting to $481,500.00.
About Bausch Health Companies Inc (NYSE:BHC)
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal. The company also develops and markets products that treat gastrointestinal and hepatologic conditions comprising hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler's diarrhea, opioid-induced constipation, ulcerative colitis, and others. In addition, it offers eye health products, such as contact lens; products that treat various eye conditions, including glaucoma, eye allergies, conjunctivitis, dry eye, and retinal diseases; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for the treatment of cataracts, and vitreous and retinal eye conditions. Further, the company provides products in the therapeutic areas of epilepsy, migraines, depression, chronic pain, and rare diseases such, as huntington's disease; and oral health products for adult periodontitis and mouth dryness, as well as teeth-whitening. Additionally, it offers eye drops; skin care products, including moisturizers; and eye vitamins and mineral supplements, as well as neurology products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.
Recent Trading Activity for Bausch Health Companies Inc (NYSE:BHC)
Shares of Bausch Health Companies Inc closed the previous trading session at 22,38 −0,49 2,14 % with 22.93 shares trading hands.